Precision BioSciences, Inc.

Healthcare · Biotechnology · United States

Last price 7.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 205.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ...